Pandemic flu vaccine: are we doing enough?

Clin Pharmacol Ther. 2007 Dec;82(6):633-5. doi: 10.1038/sj.clpt.6100417.

Abstract

Influenza experts have been trying for a long time to convince other scientists, the public health community, and the general population that preparations for a pandemic should be a priority. But it was not until the highly pathogenic H5N1 avian strain emerged, causing a great epizootic and infecting and killing people exposed to infected birds, that research on this topic exploded. Below I discuss some truly phenomenal advances that have emerged from this newfound interest in pandemic influenza, to show that, yes, we are doing enough.

Publication types

  • Historical Article

MeSH terms

  • Adamantane / pharmacology
  • Adamantane / supply & distribution
  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / supply & distribution
  • Disease Outbreaks* / history
  • Drug Approval
  • Drug Design
  • Drug Resistance, Viral
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / supply & distribution
  • History, 20th Century
  • Humans
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza A Virus, H5N1 Subtype / immunology*
  • Influenza Vaccines* / history
  • Influenza Vaccines* / pharmacology
  • Influenza Vaccines* / supply & distribution
  • Influenza in Birds / epidemiology
  • Influenza in Birds / prevention & control
  • Influenza, Human / epidemiology*
  • Influenza, Human / history
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Neuraminidase / antagonists & inhibitors
  • Oseltamivir / pharmacology
  • Oseltamivir / supply & distribution
  • Poultry / virology
  • United States
  • United States Food and Drug Administration

Substances

  • Adjuvants, Immunologic
  • Antiviral Agents
  • Enzyme Inhibitors
  • Influenza Vaccines
  • Oseltamivir
  • Neuraminidase
  • Adamantane